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1. Introduction
  Acute leukemia (AL) is a hematological disease originated 
from the malignant proliferation, differentiation and 
apoptosis of hematopoietic stem cell. Epidemiological 
survey showed that the AL occurrence is closely related 
the environment, occupation and genetic factors, and 
among them the genetic factor is considered to be the most 
important[1,2]. Studies have shown that chemokine receptor 
(CXCR) is related to the occurrence, development and 
metastasis of cancer. Cell growth and proliferation were 
regulated by many regulatory factors. The high affinity 
of CXCR2 can be combined with many chemokines and 
mediated inflammation. As one of the important CXCR 
family members, it plays an important role in leukemia cell 
survival, invasion and metastasis[3]. Recently, CXCR7 was 
discovered as one of the members of the CXCR family. There 
is not much research on the effects of CXCR2 and CXCR7 
on acute leukemia at home and abroad. Based on the above 
background, this paper detected the bone marrow CXCR2 
and CXCR7 expressions of the mice bone marrow in the 
observation group, and the control group by flow cytometry 
and RT-PCR, then compared the differences, and made a 
preliminary study on the relationship of CXCR2 and CXCR7 
with acute leukemia.
2. Materials and methods
2.1. Construction of materials and animal models
  Acute myeloid leukemia cell line HL60 cells were 
provided by the hematology department laboratory of 
medical college of southern medical university. All BALB/ N 
female nude mice 55 were purchased from the Experimental 
Animal Center of Southern Medical University, which were 
divided into the observation group (n=40) and the control 
group (n=15). The observation group was first irradiated by 
3Gy60CO, after observing for 24 h, gave 4×106 HL60 cells in 
logarithmic growth phase by intraperitoneal injection, the 
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control group were injected with the same volume of 0.2 mL 
normal saline without irradiation.
2.2. Reagents and instruments
  Anti-mouse CXCR2-PE monoclonal antibody, anti-mouse 
CXCR7-PE monoclonal antibody were purchased from BD 
Biosciences, Trizol, chloroform, RT-PCR kit, DEPC, TaKaRa 
TaqTM, DNA Marker (DL-2000) were purchased from TAKARA 
corporation, DaLian. Flow cytometry was purchased from 
Beckman Coulter Corporation, 37 degrees incubator was 
purchased from Beijing Changfeng Instrument Factory, 
PCR amplification was purchased from British Techne 
Corporation, gel imaging analyzer was purchased from Sigma 
(USA), ultra-low temperature freezer was purchased from 
China Haier.
2.3. Methods
2.3.1. CXCR 2, CXCR7 expressions of bone marrow cells by 
flow cytometry
  Fresh bone marrow 2 mL was collected, and placed in 
ordinary centrifuge at 1 700 rpm. It was centrifuged for 5 min 
at room temperature, and the supernatants were removed. 
The middle layer of white blood cells was removed into 
another clean test tube. 3 mL PBS buffer solution was added, 
and it was centrifuged for 5 minutes at 1 500 rpm, room 
temperature, then supernatant were abandoned. 100 毺L PBS 
buffer solution was added, and 25 毺L of the mixture liquid 
was injected into three clean EP tubes. 10毺L PE-CXCR2 
antibody, PE-CXCR7 antibody and isotype control antibody 
was added respectively, then was mixed after repetitive beat 
by pipette and incubated at 4 曟 refrigerator for 45 minutes.
4 mL PBS buffer solution was added and centrifuged for 
5 min at 500 rpm, supernatant was abandoned. 200 毺L
PBS buffer solution was added, and it was placed in the 
flow cytometry. 488 nm wavelength was selected for flow 
detection.
2.3.2. CXCR2, CXCR7 expressions by RT-PCR
  Fresh bone marrow were collected at asepsis into EDTA 
tubes, lymphocyte separation medium were obtained 
and mononuclear cells were isolated by density gradient 
centrifugation. It was washed with PBS buffer twice, 
centrifuged at 1 500 rpm for 5 minutes at room temperature, 
the supernatants were removed. After blotting up, it was 
frozen and preserved at -80 曟. Total RNA was extracted 
by one-step Trizol, the samples OD260/OD280 ratio was 
controlled in a range from 1.8-2.0. cDNA synthesis was 
carried out. The primer sequence and primers were designed 
by Shanghai Sangon Biological Engineering Services Ltd. 
CXCR2 upstream primer: CTT TTC TAC TAG ATG CCG C, 
downstream primer AGA TGC TGA GAC ATA TGA ATT T, 
amplified product was 417 bp; CXCR7 upstream primer: 
TGG GTG GTC AGT CTC GT, downstream primer CCG GCA 
GTA GGT CTC AT, amplified product was 294 bp; GAPDH 
was used as an internal control, upstream primer: ACC ACA 
GTC CAT GCC ATC AC, downstream primer TCC ACC ACC 
CTG TTG CTG TA, amplified product was 452 bp. The total 
reaction volume was 20 毺L, amplification condition was 
94  曟, pre-denatured for 2 min; it was denatured at 94 曟 
for 30 s, primer annealing at 55 曟/53 曟 for 30 s, extension 
at 72  曟 for 1 min, 30 cycles in total, then it was stopped at 
4 曟. After that, 5 毺L product was obtained for 2% agarose 
gel electrophoresis. Quantity-One software was used for 
image gray scale analysis, internal reference GAPDH optical 
density values were used to standardized CXCR2 and CXCR7 
mRNA absorbance values, CXCR2/GAPDH and  CXCR7/
GAPDH ratio was used as the relative content of CXCR2 and 
CXCR7 expression levels.
2.4. Statistical analysis
  All data was analyzed with SPSS 16.0 software. Semi-
quantitative expression levels of CXCR7 and CXCR2 were 
non-normal distribution, the measurement data was 
expressed as the median. The two samples rates or several 
sample rates of the enumeration data were evaluated by 
pearson Chi-Square. Two independent samples were 
compared by wilcoxon rank sum test. Correlation analysis 
was analyzed with the Speraman correlation analysis.
毩=0.05 is the level of significance, P<0.05 was regarded as 
statistically significant difference.
3. Results
3.1. Flow cytometry detection of bone marrow mononuclear 
cells CXCR2 and CXCR7 expression
  CXCR2 expression in the observation group [(13.5依4.0)%]
was significantly higher than that in the control group [(2.4依
1.3)%] (P=0.01),and the CXCR7 expression of the observation 
group [(9.3依2.6)%] was significantly higher than that in the 
control group [(2.7依1.7)%] (P=0.003).
3.2. CXCR2 and CXCR7 gene expression
  CXCR2 mRNA median expression levels of the observation 
group and the control group were 0.389 (0.173-0.658) and 
0.074 (0.032-0.111) respectively, the CXCR2 expression in the 
observation group was significantly higher than that in the 
control group (P=0.008). CXCR7 mRNA median expression 
levels of the observation group and the control group were 
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0.422 (0.065-0.795) and 0.069 (0.037-0.122) respectively, the 
CXCR7 expression in the observation group was significantly 
higher than that in the control group (P=0.004).
3.3.Correlation analysis
  CXCR2 and CXCR7 relative fluorescence intensity of the 
nude mice in the observation group were determined by the 
spearman rank correlation coefficient test, the result showed 
positive relationship between CXCR2 and CXCR7 (r=0.782, 
P<0.01).
4. Discussion
  Tumorigenesis is a multi-step, multi-stage and multi-
gene complex process, which is the final manifestation of 
the loss of control of cell growth and proliferation. After 
analysis on all the factors of cell growth and proliferation, it 
is considered that the chemokine receptor is closely related 
to the tumor occurrence[5-12]. Chemokine receptor belongs 
to the seven transmembrane G protein-coupled receptors. 
In the current seven kinds, CXCR and CXCR2 can combine 
with most of the chemokine receptors and participate in the 
body’s inflammation and defense responses[13]. Oladipo et 
al considered that it can be expressed moderately in human 
microvascular endothelial cells and promote the vascular 
endothelial cell survival, proliferation and inhibit apoptosis, 
which then play an important role in the producing process 
of the tumor blood vessels[14-19]. CXCR7 is a new family 
member of the chemokine receptor with less expression in 
normal cells, while it can be mainly seen in tumor cell lines, 
activated endothelial cells, as well as fetal liver cells. Maciej 
considered that CXCR7 is highly expressed in leukemia 
cells, which can produce chemotaxis and induce neutrophil 
cell migration, then mediated large number of neutrophils 
locally concentrated which lead to peripheral tissue damage 
and increase the probability of cancer[20-25]. A number 
of studies by domestic and foreign scholars indicate that 
SDF-1/CXCR ligand system can activate many intracellular 
signaling pathways which lead to the activation of some 
transcription factors, such as interleukin-8 (IL-8), NF-kB, 
etc. The activation of the transcription factor can further 
promote endogenous chemokine and receptor expressions, 
while many of the transcription factor itself (IL-8, NF-kB) 
can form tumor molecular biomarker, thus promote tumor 
growth[26,27]. The study found that the bone marrow CXCR2 
and CXCR7 expressions in nude mice with acute leukemia 
were significantly higher than non-maligance hematology 
disease nude mice, the bone marrow CXCR2 mRNA 
expression in acute lymphoblastic leukemia nude mice 
was higher than the non-hematologic malignancies nude 
mice, the CXCR7 mRNA expression in acute lymphoblastic 
leukemia nude mice was higher than the non-hematologic 
malignancies nude mice, and the CXCR2 and CXCR7 
relative fluorescence intensity were positively correlated 
in the AL nude mice. We considered the high expression 
of CXCR2 and CXCR7 may be related to the occurrence 
of acute leukemia, and some literature suggests that the 
CXCR7 expression was significantly higher than CXCR2 of 
patients with acute leukemia extramedullary infiltration, 
which showed that CXCR7 high expression is closely related 
to its development and occurrence of this disease. Although 
some studies show that the CXCR7 expression levels is low 
in vitro, Burton et al analyzed blood samples of tumor cell 
lines by RT-PCR and flow cytometry, the results show that 
the acute leukemia has high expression of CXCR7, which is 
consistent with our results.
  There is less research on CXCR2 in hematological tumor, 
but studies at home and abroad all considered CXCR2 can 
be activated by a variety of upstream factors. CXCR2 itself 
can promote high expression by autocrine or paracrine 
activation pathways, and then activated partial transcription 
factor by the activation of many cells intracellular signal 
transduction pathways, and can promote angiogenesis and 
tumor growth by the partial migration of chemotaxis vascular 
endothelial cells[28,29]. SINGH S can inhibit the growth of 
various tumors by blocking the function of CXCR2, further 
proved that CXCR2 possesses an angiogenesis effect and 
produce consistent effects in different tumor development 
processes[30].
  In summary, the roles and relationship of CXCR2 and 
CXCR7 in hematological malignances have become the 
focus recently. With the increasing understanding of 
the relationship between CXCR2 and CXCR7 with acute 
leukemia and the invasive mechanism, its antagonists can 
provide new ideas and methods in the clinical treatment 
process.
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